[Skip to Content]
[Skip to Content Landing]
Views 1,082
Citations 0
Invited Commentary
November 2015

Precision Medicine in Breast Cancer CareAn Early Glimpse of Impact

Author Affiliations
  • 1Department of Medicine, Stanford University School of Medicine, Stanford, California
  • 2Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California
  • 3Department of Systems, Populations and Leadership, University of Michigan School of Nursing, Ann Arbor
  • 4Institute for Healthcare Policy and Innovation, University of Michigan School of Nursing, Ann Arbor
JAMA Oncol. 2015;1(8):1109-1110. doi:10.1001/jamaoncol.2015.2719

Precision medicine—the concept of targeting therapy to a patient’s unique genetic or other relevant characteristics—occupies a prominent place on the national agenda.1 No condition demonstrates recent efforts toward precision medicine more clearly than cancer, and particularly breast cancer. After a decade of molecular subtyping, increasingly comprehensive genomic tests are emerging into breast cancer care. The 21-gene recurrence score (RS) assay has led the way in clinical implementation and thus offers an early opportunity to measure the impact of precision medicine on cancer treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview
×